{
  "ticker": "MRSN",
  "company_name": "Mersana Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05377996",
      "title": "A Study of XMT-1660 in Participants With Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma",
      "start_date": "2022-08-15",
      "completion_date": "2027-05",
      "enrollment": 0,
      "sponsor": "Mersana Therapeutics"
    },
    {
      "nct_id": "NCT05514717",
      "title": "A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer, HER2-positive Tumors, HER2 Low Breast Cancer",
      "start_date": "2023-01-24",
      "completion_date": "2027-04",
      "enrollment": 0,
      "sponsor": "Mersana Therapeutics"
    },
    {
      "nct_id": "NCT02952729",
      "title": "Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Advanced Breast Cancer, Advanced Nonsmall Cell Lung Cancer, Advanced Gastric Cancer",
      "start_date": "2016-11-21",
      "completion_date": "2019-01-28",
      "enrollment": 0,
      "sponsor": "Mersana Therapeutics"
    },
    {
      "nct_id": "NCT04907968",
      "title": "Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Platinum-sensitive Ovarian Cancer (UPGRADE-A)",
      "start_date": "2021-06-11",
      "completion_date": "2023-10-03",
      "enrollment": 0,
      "sponsor": "Mersana Therapeutics"
    },
    {
      "nct_id": "NCT00455052",
      "title": "A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Small Cell Lung Cancer, Non-small Cell Lung Cancer",
      "start_date": "2011-03",
      "completion_date": "2011-12",
      "enrollment": 0,
      "sponsor": "Mersana Therapeutics"
    },
    {
      "nct_id": "NCT01011972",
      "title": "A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Neoplasm Metastasis",
      "start_date": "2010-03",
      "completion_date": "2013-09",
      "enrollment": 0,
      "sponsor": "Mersana Therapeutics"
    },
    {
      "nct_id": "NCT06517433",
      "title": "First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic",
      "start_date": "2017-12-12",
      "completion_date": "2021-07-09",
      "enrollment": 0,
      "sponsor": "Mersana Therapeutics"
    },
    {
      "nct_id": "NCT05329545",
      "title": "Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer",
      "start_date": "2022-06-23",
      "completion_date": "2023-09-29",
      "enrollment": 0,
      "sponsor": "Mersana Therapeutics"
    },
    {
      "nct_id": "NCT04396340",
      "title": "First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Ovarian Cancer, Nonsmall Cell Lung Cancer",
      "start_date": "2020-05-11",
      "completion_date": "2022-09-30",
      "enrollment": 0,
      "sponsor": "Mersana Therapeutics"
    },
    {
      "nct_id": "NCT03319628",
      "title": "First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic",
      "start_date": "2017-12-12",
      "completion_date": "2024-10-31",
      "enrollment": 0,
      "sponsor": "Mersana Therapeutics"
    }
  ],
  "summary": {
    "total_trials": 11,
    "by_phase": {
      "PHASE1": 9,
      "PHASE3": 1,
      "PHASE1, PHASE2": 1
    },
    "by_status": {
      "RECRUITING": 2,
      "COMPLETED": 5,
      "TERMINATED": 3,
      "ACTIVE_NOT_RECRUITING": 1
    },
    "active_trials": 3,
    "completed_trials": 5,
    "conditions": [
      "Advanced Breast Cancer, Advanced Nonsmall Cell Lung Cancer, Advanced Gastric Cancer",
      "HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer, HER2-positive Tumors, HER2 Low Breast Cancer",
      "High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer",
      "Neoplasm Metastasis",
      "Ovarian Cancer, Nonsmall Cell Lung Cancer",
      "Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic",
      "Platinum Resistant Ovarian Cancer, Non-Small Cell Adenocarcinoma",
      "Platinum-sensitive Ovarian Cancer (UPGRADE-A)",
      "Small Cell Lung Cancer, Non-small Cell Lung Cancer",
      "Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:20:07.935334",
    "search_query": "Mersana Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Mersana+Therapeutics,+Inc."
  }
}